Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 4 of 79. Open to participants first (2,630), then studies with results posted, then the rest; newest registration first within each.

• Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07565389Phase 2
• Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination DeficiencyNot yet recruitingNCT07565155Phase 2
• NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor MalignanciesRecruitingNCT07563829Phase 1
• Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLCNot yet recruitingNCT07561983Phase 2
• Adebrelimab Plus S-1 for Resected CholangiocarcinomaNot yet recruitingNCT07561775Phase 2
• Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab ImmunotherapyRecruitingNCT07561060Phase 1/2
• Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Phase 2
• Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Phase 2
• Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Phase 2
• Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：ChaseRecruitingNCT07555678Phase 2
• A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesRecruitingNCT07554521Phase 2
• Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/2
• Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingNCT07551596Phase 2
• Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingNCT07551583Phase 2
• SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal CancerNot yet recruitingNCT07551479Phase 3
• Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort StudyNot yet recruitingNCT07549906Phase 2
• SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RCRecruitingNCT07549399Phase 3
• A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT07546383Not applicable
• Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Not yet recruitingNCT07545083Phase 2
• A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal CancerNot yet recruitingNCT07543848Phase 2
• Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 TrialNot yet recruitingNCT07543783Phase 2
• Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersEnrolling by invitationNCT07542262Phase 2
• A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast CancerRecruitingNCT07540533Phase 2
• A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07538271Phase 2
• Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingNCT07538258Phase 2
• Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Phase 2
• A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicable
• Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07535567Phase 2/3
• A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerRecruitingNCT07535463Phase 1/2
• Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533305Phase 2
• Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Not yet recruitingNCT07531979Phase 2
• A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant ChemoimmunotherapyNot yet recruitingNCT07530549Phase 2
• Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruitingNCT07530445Phase 2
• Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07530094Phase 2
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureRecruitingNCT07528274Phase 2
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2
• Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II TrialNot yet recruitingNCT07527520Phase 2
• Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaNot yet recruitingNCT07527325Phase 2
• A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal CancerRecruitingNCT07527026Phase 2
• Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07523737Phase 2
• Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction CancerRecruitingNCT07522151Phase 3
• Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingNCT07521605Phase 2
• EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingNCT07518979Phase 2
• Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
• A Study of Ivonescimab in People With LeiomyosarcomaRecruitingNCT07516925Phase 2
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingNCT07516366Phase 2
• Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07515625Phase 2
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence RiskNot yet recruitingNCT07515469Phase 2
• Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingNCT07514767Phase 2
• A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)RecruitingNCT07513376Phase 3
• Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2
• PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingNCT07511036Phase 2
• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingNCT07510594Phase 2
• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2
• Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal CanceNot yet recruitingNCT07509424Phase 2
• TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal AdenocarcinomaNot yet recruitingNCT07507968Phase 2
• Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07507916Phase 2
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2
• Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard TherapyRecruitingNCT07506057Phase 2
• Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Phase 2
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingNCT07504796Phase 2
• Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingNCT07503639Phase 2
• Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRecruitingNCT07502768Phase 1/2
• A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07502027Phase 4
• Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck CancerRecruitingNCT07501650Phase 1
• Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 1
• Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell CarcinomaNot yet recruitingNCT07500831Not applicable
• Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal CancerRecruitingNCT07500298Phase 1
• Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07492914Phase 2
• A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07492615Phase 2
• A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Phase 2/3
• Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2
• SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLCNot yet recruitingNCT07489703Phase 2
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCRecruitingNCT07489066Phase 2
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskNot yet recruitingNCT07487662Phase 2
• Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3
• A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07485920Phase 4
• A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07484724Phase 2
• IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07483567Phase 2
• Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaRecruitingNCT07476326Phase 1
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerRecruitingNCT07476287Phase 2
• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2
• A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
• SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARCRecruitingNCT07474103Not applicable
• SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingNCT07472517Phase 3
• Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)RecruitingNCT07472478Phase 2
• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1Not yet recruitingNCT07472322Phase 1/2
• PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical CancerRecruitingNCT07472153Phase 2/3
• Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 2
• Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingNCT07469956Phase 2
• Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingNCT07468136Phase 1/2
• Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingNCT07466927Phase 2
• A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical CancerNot yet recruitingNCT07466901Not applicable
• Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingNCT07466303Phase 2
• A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsRecruitingNCT07466160Phase 1/2
• Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCRecruitingNCT07465276Phase 2
• Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver ResectionNot yet recruitingNCT07461675Phase 3
• Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07460765Phase 1

← Immune Checkpoint Inhibitors overview